Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.57 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535136 | 1.00 | GRIN2B (0.57) | GRIN2BGRIN2CCDK4MMP1MMP2 | |
| SCHEMBL3533735 | 1.00 | GRIN2B (0.57) | GRIN2BGRIN2CCDK4MMP1MMP2 | |
| SCHEMBL3535138 | 1.00 | GRIN2B (0.57) | GRIN2BGRIN2CCDK4MMP1MMP2 | |
| SCHEMBL23835781 | 0.87 | GRIN2B (0.63) | GRIN2BGRIN2CCDK4JAK3TSHR | |
| SCHEMBL24740823 | 0.83 | GRIN2B (0.58) | GRIN2BGRIN2CCDK4JAK3TSHR | |
| SCHEMBL30008265 | 0.82 | GRIN2B (0.48) | GRIN2BGRIN2CCDK4JAK3 | |
| SCHEMBL30008807 | 0.82 | GRIN2B (0.48) | GRIN2BGRIN2CCDK4JAK3 | |
| SCHEMBL19229634 | 0.80 | GRIN2B (0.70) | GRIN2BGRIN2CCDK4JAK3 | |
| SCHEMBL24339067 | 0.80 | GRIN2B (0.84) | GRIN2BGRIN2CCDK4JAK3TSHR | |
| SCHEMBL30310450 | 0.79 | GRIN2B (0.46) | GRIN2BGRIN2CCDK4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655686-B2 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| EP-1670803-B1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070265328-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | AUBERSON YVES | 2007-01-18 | — | — | US | disclosed |
| EP-1670803-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | Novartis AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005035535-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265328-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | STS, RPS6KA5, RPIA | GRIN2B 2525/4885GRIN2C 1610/4885CDK4 268/4885 |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | STS, RPS6KA5, RPIA | GRIN2B 2525/4885GRIN2C 1610/4885CDK4 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.